Dean

Dr. Bugden trained as a pharmacist and completed post-graduate work at the University of Manitoba, with additional post-graduate studies at the University of Washington and the University of Oxford. For over a decade, he worked in hospital pharmacy management with a special interest in pharmacy practice in rural and remote Canada, where he has worked in both the hospital and community sectors. His research is focused on the optimal use of medications. His work in evidence-based medicine and pharmacoepidemiology helps clinicians make the best possible decisions on medication use.

Research areas of interest: Pharmacoepidemiology, pharmacoeconomics, drug utilization, medication safety, opioid stewardship, health policy, pharmacy practice

Teaching areas of interest: Pharmacoepidemiology, pharmacoeconomics, biostatistics, critical appraisal, evidence-based medicine

Current projects:

• Drug Safety and appropriate medication use in dementia
• Opioid utilization, stewardship and health policy
• Over diagnosis and over-treatment (diabetes and COPD)
• Pharmacy health human resources policy

Selected awards:

2024 Canadian Pharmacists Association’s (CPhA) Past Presidents Award
2018 Continuing Competency and Assessment (CCA) Educator of the Year
2018 Honorary Life Member, College of Pharmacists of Manitoba
2017 Outstanding Teacher 3rd Year, College of Pharmacy, University of Manitoba
2016 Merit Award, University of Manitoba
2015 Pharmacist of the Year, College of Pharmacists of Manitoba
2010 Centennial Award, College of Pharmacist of Manitoba
2009 Award of Merit, Pharmacists Manitoba

Selected publications:

Nguyen HV, Mital S, Bugden S, McGinty E 2024. British Columbia’s safer opioid supply policy and opioid outcomes. JAMA Intern Med 184(3):256-264. 

Friesen KJ, Falk J, Chateau D, Kuo I, Bugden S. 2023. Signal and noise: Proton-pump-inhibitors and the risk of dementia. Clinical Pharmacy and Therapeutics. 113:152-159.

Davis E, Lee T, Weber JT, Bugden S. 2020. Cannabis use in pregnancy and breastfeeding: The pharmacist's role. Can Pharm J. 153(2):95-100.

Douros A, Lix LM, Fralick M, Dell'Aniello S, Shah BR, Ronksley PE, Tremblay É, Hu N, Alessi-Severini S, Fisher A, Bugden SC, Ernst P, Filion KB. 2020.  Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis: A Multicenter Cohort Study. Ann Intern Med. 173(6):417-425.

Filion KB, Lix LM, Yu OH, Dell'Aniello S, Douros A, Shah BR, St-Jean A, Fisher A, Tremblay E, Bugden SC, Alessi-Severini S, Ronksley PE, Hu N, Dormuth CR, Ernst P, Suissa S; Canadian Network for Observational Drug Effect Studies (CNODES) Investigators. 2020. Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study. BMJ 370:m3342.

Henry D, Dormuth C, Winquist B, Carney G, Bugden S, Berard A, Platt R. 2016. Occurrence of pregnancy and pregnancy outcomes in women taking isotretinoin in Canada. Canadian Medical Association Journal. 188(10):723-730.

Falk J, Dahl M, Raymond C, Chateau D, Katz A, Leong C, Bugden S. 2017. Opioid use during pregnancy: a population-based cohort study. CMAJ Open. 5(2): E517-E523.

Friesen K, Woelk C, Bugden S. 2016. Safety of fentanyl initiation according to past opioid exposure among patients newly prescribed fentanyl patches. Canadian Medical Association Journal. 188(9):648-653.

Serwylo O, Friesen K, Falk J, Bugden S. 2016. Opportunity Cost and Policy: A Utilization Review of Self-Monitoring of Blood Glucose in Manitoba, Canada. Clinical Therapeutics. 38(4):929-935.

Contact:
shawn.bugden@mun.ca
Tel: 709-864-4400